Stock Analiz

Enlivex Ltd. ENLV

Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026

$1.19Market cap $2M
Open the interactive analysis →

Enlivex Ltd. (ENLV) is a healthcare company listed in the US with a market value of about $2M.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).

Key numbers: a P/E of 0.0, a 5-year average ROIC of -36%.

About Enlivex

Enlivex is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. It was profitable in 1 of the last 10 years in our data.

Score: 1.0 / 5

Value2/5
Future growth0/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)0.0
Forward P/E—
P/FCF—
P/S—
P/B0.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-575.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-35.6%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue——————————
Net income$1.2B-$15M-$29M-$31M-$14M-$12M-$9M-$4M-$3M-$16M
Free cash flow-$10M-$13M-$24M-$32M-$19M-$12M-$7M-$4M-$2M-$16M
EPS (diluted)$806.48$-9.80$-18.97$-20.27$-9.44$-7.72$-6.13$-2.77$-1.63$-10.46
Net margin——————————
ROIC-0.6%-52.0%-74.6%-33.0%-17.9%-21.8%-60.4%-54.5%-20.2%-446.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Enlivex’s P/E ratio?

About 0.0, based on the last twelve months of diluted earnings per share.

Does Enlivex pay a dividend?

Not currently.

Is Enlivex a good stock to buy?

We do not give buy or sell advice. Enlivex scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.